Related Experiment Videos
A percutaneously accessible pulsatile left ventricular assist device: modified assist device type 5
K Imanishi1, K Imachi, H Yoshito
1Department of Cardiovascular Surgery, Tokyo Women's Medical College, Daini Hospital, Japan.
Artificial Organs
|February 1, 1996
Summary
A novel modified assist device (MAD) offers percutaneous circulatory support. This innovative system effectively unloads the left ventricle and augments aortic flow, demonstrating potential for enhanced systemic and coronary circulation.
Area of Science:
- Cardiovascular Engineering
- Medical Devices
- Hemodynamics
Background:
- Percutaneous access for circulatory assist remains a critical challenge in cardiovascular medicine.
- Existing systems often require invasive surgical procedures.
- There is a need for minimally invasive circulatory support devices.
Purpose of the Study:
- To develop and evaluate a novel percutaneously accessible circulatory assist system.
- To assess the performance of the modified assist device (MAD) in vitro and in vivo.
- To determine the potential of the MAD to improve systemic and coronary blood flow.
Main Methods:
- Development of a sac-type blood pump and cannula system, termed the modified assist device (MAD).
- Inflow and outflow valves were strategically placed on the cannula for efficient blood management.
- In vitro testing in a mock circulatory system and in vivo animal experiments were conducted to evaluate pump performance.
Main Results:
- The modified assist device (MAD) achieved a maximum flow rate of 1.9 L/min in the mock circulatory system.
- In vivo animal studies demonstrated effective systolic unloading of the left ventricle.
- The system also showed significant diastolic augmentation of aortic flow during regular sinus rhythm.
Conclusions:
- The modified assist device (MAD-5) is designed for percutaneous accessibility, offering a less invasive approach to circulatory support.
- The device effectively unloads the left ventricle during systole and augments flow during diastole.
- The MAD-5 shows promise in increasing both systemic and coronary blood flow, potentially improving outcomes in patients with cardiovascular compromise.